Search | Clinical Trials Finder

Conditions: Crohn Disease
Interventions: Sargramostim (Leukine), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 47
States / cities: Huntsville, Alabama • Orange, California • San Francisco, California + 43 more

Conditions: Prostate Cancer
Interventions: sipuleucel-T, Placebo; Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 34
States / cities: Duarte, California • Loma Linda, California • Rancho Mirage, California + 26 more

Conditions: Multiple Myeloma
Interventions: GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine; Biological · Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Interventions: GM-CSF, Placebo; Drug · Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Day to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 21 more

Conditions: COVID
Interventions: mavrilimumab, Placebo; Drug · Other
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years and older
Enrollment: 814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Chicago, Illinois + 6 more

Conditions: Parkinson's Disease
Interventions: sargramostim, placebo, Sham Comparator: Controls; Drug · Diagnostic Test
Lead sponsor: University of Nebraska; Other
Eligibility: 35 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Omaha, Nebraska

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 60 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 91
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more

Conditions: Prostate Cancer
Interventions: Sipuleucel-T, APC-Placebo; Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 65
States / cities: Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more

Conditions: Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions: pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF; Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Orlando, Florida • Durham, North Carolina

Conditions: Moderate-to-Severe Asthma
Interventions: Anti-GM-CSF Monoclonal Antibody 400mg, Placebo; Biological · Other
Lead sponsor: Humanigen, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Fullerton, California • Granada Hills, California + 27 more

Conditions: Crohn Disease
Interventions: Sargramostim (Leukine), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • New Orleans, Louisiana + 4 more

Conditions: Peripheral Artery Disease (PAD)
Interventions: GM-CSF, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Molgramostim, Placebo, Molgramostim Open-label; Drug
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar; Drug
Lead sponsor: Epitopoietic Research Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 3
States / cities: Orange, California • Boston, Massachusetts

Conditions: HIV Infections
Interventions: APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Rochester, New York + 1 more

Conditions: Alzheimer's Disease
Interventions: Sagramostim, Saline -- placebo comparator; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Cancer Metastatic
Interventions: PROSTVAC-V, PROSTVAC-F, GM-CSF, GM-CSF Placebo, Placebo; Biological · Drug · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 84
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more

Conditions: Peripheral Arterial Disease
Interventions: Supervised Treadmill Exercise Therapy, Health education sessions (Control), granulocyte macrophage colony stimulating factor (GM-CSF); Behavioral · Other · Drug
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: HIV CTL MEP 1000 micrograms, 19 months per subject; Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 10
States / cities: Sacramento, California • Denver, Colorado • Chicago, Illinois + 6 more

Conditions: Melanoma
Interventions: Talimogene Laherparepvec, Pembrolizumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more

Conditions: Peripheral Arterial Disease
Interventions: Granulocyte-Macrophage Stimulating Factor (GM-CSF), Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more

Conditions: Dementia Alzheimer's Type
Interventions: Sargramostim GZ402664, Placebo, Florbetapir F18; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy; Drug · Procedure
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Beverly Hills, California • Chapel Hill, North Carolina

Search by objective public record fields.

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Leukine (Sargramostim) for Parkinson's Disease

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

Study Evaluating Vaccine in Adults With HIV

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma